

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

T2

RRID:CVCL_2211

Type: Cell Line

Proper Citation

CLS Cat# 305228, RRID:CVCL_2211

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2211

Proper Citation: CLS Cat# 305228, RRID:CVCL_2211

Description: Cell line T2 is a Hybrid cell line with a species of origin Homo sapiens (Human)

Defining Citation: [PMID:1373173](#), [PMID:3872841](#)

Category: Hybrid cell line

Organism: Homo sapiens (Human)

Name: T2

Synonyms: T2 (174 x CEM.T2), T2(174 x CEM.T2), 174xCEM.T2, CEMx721.174.T2

Cross References: BTO:BTO_0003771, CLO:CLO_0009242, CLO:CLO_0050160, EFO:EFO_0022680, ATCC:CRL-1992, BioSample:SAMN03471271, BioSample:SAMN03472034, CLS:305228, DSMZ:ACC-598, DSMZCellDive:ACC-598, Hysigen:TCH-C419, Lonza:926, NCBI_Iran:C509, RCB:RCB1932, TKG:TKG 0599, TOKU-E:3251, Wikidata:Q54971430

ID: CVCL_2211

Vendor: CLS

Catalog Number: 305228

Hierarchy: cvcl_7904

Record Creation Time: 20250423T102441+0000

Record Last Update: 20260905T185133+0000

Ratings and Alerts

No rating or validation information has been found for T2.

No alerts have been found for T2.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Rubin AJ, et al. (2026) Disordered protein LAT encodes relative levels of signaling pathways in T cell activation. Science (New York, N.Y.), 392(6797), eads6847.

Gaglione SA, et al. (2026) Scalable TCR synthesis and screening enable antigen reactivity mapping in vitiligo. Immunity, 59(2), 477.

Wang S, et al. (2025) IFN- γ -driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. Nature communications, 16(1), 10733.

Fusi I, et al. (2025) PD-1-targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer. Science translational medicine, 17(816), eadr3718.

Kim WJ, et al. (2025) Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias. Cell, 188(13), 3422.

Venetz-Arenas N, et al. (2025) Development of DARPin T cell engagers for specific targeting of tumor-associated HLA/peptide complexes. iScience, 28(12), 113926.

Zhang T, et al. (2024) Comparison of Shared Class I HLA-bound Non-canonical Neoepitopes between Normal and Neoplastic Tissues of Pancreatic Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research.

Füchsl F, et al. (2024) High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells. Nature communications, 15(1), 10520.

Sim MJW, et al. (2024) Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3. European journal of immunology, e2451079.

Amissah OB, et al. (2024) NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal

cancer: a dual-targeted cancer therapeutic route. *Cancer cell international*, 24(1), 64.

Wohlfarth J, et al. (2024) Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density. *Molecular oncology*, 18(10), 2449.

Kortleve D, et al. (2024) TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer. *Cancer discovery*, 14(12), 2450.

Di Modugno F, et al. (2024) Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer. *EBioMedicine*, 101, 105003.

Schmidt F, et al. (2023) In-depth analysis of human virus-specific CD8⁺ T cells delineates unique phenotypic signatures for T cell specificity prediction. *Cell reports*, 42(10), 113250.

Trefny MP, et al. (2023) Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy. *Nature communications*, 14(1), 86.

Iizuka A, et al. (2023) Generation of novel complete HLA class I monoallelic cell lines used in an MHC stabilization assay for neoantigen evaluation. *Oncology letters*, 26(2), 324.

Kawai A, et al. (2023) Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(24), 5069.

Ishihara M, et al. (2023) α -T cell receptor transduction gives superior mitochondrial function to α -T cells with promising persistence. *iScience*, 26(10), 107802.

Immisch L, et al. (2023) Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors. *Frontiers in immunology*, 14, 1119498.

Chirioiu GN, et al. (2023) Methionine oxidation selectively enhances T cell reactivity against a melanoma antigen. *iScience*, 26(7), 107205.